EP0349428A1 - Verfahren zur Herstellung von kolloidalen dispergierbaren Proteinsystemen, wie Nanopartikeln - Google Patents
Verfahren zur Herstellung von kolloidalen dispergierbaren Proteinsystemen, wie Nanopartikeln Download PDFInfo
- Publication number
- EP0349428A1 EP0349428A1 EP89401856A EP89401856A EP0349428A1 EP 0349428 A1 EP0349428 A1 EP 0349428A1 EP 89401856 A EP89401856 A EP 89401856A EP 89401856 A EP89401856 A EP 89401856A EP 0349428 A1 EP0349428 A1 EP 0349428A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- protein
- nanoparticles
- water
- biologically active
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 44
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 38
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 38
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229940088623 biologically active substance Drugs 0.000 claims abstract description 16
- 239000000725 suspension Substances 0.000 claims abstract description 15
- 239000007791 liquid phase Substances 0.000 claims abstract description 13
- 230000015271 coagulation Effects 0.000 claims abstract description 10
- 238000005345 coagulation Methods 0.000 claims abstract description 10
- 239000004094 surface-active agent Substances 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 4
- 239000002537 cosmetic Substances 0.000 claims abstract description 3
- 239000012071 phase Substances 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 11
- 102000016942 Elastin Human genes 0.000 claims description 5
- 108010014258 Elastin Proteins 0.000 claims description 5
- 229920002549 elastin Polymers 0.000 claims description 5
- 239000000084 colloidal system Substances 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 239000012798 spherical particle Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 108010071390 Serum Albumin Proteins 0.000 claims description 2
- 102000007562 Serum Albumin Human genes 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 238000013019 agitation Methods 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 20
- 239000002904 solvent Substances 0.000 description 16
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 5
- 229960004025 sodium salicylate Drugs 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000000959 cryoprotective effect Effects 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/025—Explicitly spheroidal or spherical shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/12—Powdering or granulating
- C08J3/14—Powdering or granulating by precipitation from solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
Definitions
- the present invention relates to a new process for the preparation of dispersible colloidal systems of a protein in the form of spherical particles of matrix type and of size less than 500 nm (nanoparticles).
- the present invention relates to a variant of the above method in which said substance is a protein and optionally a biologically active substance, said solvent is water or an aqueous mixture at a temperature below the coagulation temperature of the protein, said non-solvent for the substance is water at a temperature above temperature of coagulation of the protein and may optionally contain a biologically active substance, and said two liquid phases (1) and (2) are combined under pH conditions far from the isoelectric point of the protein.
- the protein is in particular a natural protein such as a serum albumin (for example human or bovine serum albumin) or an elastin (bovine, etc.).
- the biologically active substance can be a medicinal active principle or a medicinal precursor, a biological reagent or a cosmetic principle.
- the invention makes it possible to obtain protein nanoparticles alone (usable as such) or with the biologically active substance. it is also possible and even desirable in the event of thermal instability, to fix the biologically active substance on the protein nanoparticles already formed.
- the solvent of phase (1) which is water or an aqueous mixture (for example acidified or basified water) is found in particular at a temperature ranging from 0 ° to 50 ° C., for example approximately at room temperature .
- the non-solvent for the protein in phase (2) which is water or an aqueous mixture (for example acidified or basified water) is found in particular at a temperature ranging from 80 ° to 100 ° C (under atmospheric pressure), for example approximately at the boiling point.
- the pH of the mixture of phases (1) and (2) must be removed from the isoelectric point of the protein in order to avoid its flocculation. This desirable pH difference is on the order of 2 to 3. Since natural proteins often have a pH on the order of 5 to 6, it is desirable that the final solution has a pH of about 3 or about 9 To this end, the acid or the base can be added indifferently to phase (1) or (2).
- Moderate agitation is meant slight agitation of 10 to 500 rpm, p. ex. around 100 rpm, in particular by magnetic stirrer.
- the protein concentration in phase (1) can vary from 0.1 to 10%, preferably from 0.5 to 4%.
- phase (1) / phase (2) volume ratio can vary from 0.1 to 1, preferably from 0.2 to 0.6.
- colloidal solution of nanoparticles can be concentrated, sterilized, buffered (for example at physiological pH), lyophilized or crosslinked at will.
- the invention makes it possible to obtain protein nanoparticles, in particular from 150 to 300 nm.
- Example 1 Preparation of nanoparticles of human serum albumin (SAH).
- Phase 1 is added with magnetic stirring to phase 2.
- the medium immediately becomes opalescent by formation of SAH nanoparticles.
- the average size of the nanoparticles, measured in a laser beam diffractometer (Nanosizer R from Coultronics) is 190 nm with an average dispersion index of 0.5.
- the suspension can be concentrated under reduced pressure to the desired volume, for example 100 cm3.
- Example 2 Preparation of sterile human serum albumin nanoparticles.
- Example 2 The procedure is as in Example 1, then the suspension is sterilized in an autoclave at 134 ° C for 15 minutes. The average particle size remains practically unchanged after sterilization.
- Example 3 Preparation of freeze-dried human serum albumin nanoparticles.
- Example 2 The procedure is as in Example 2, then the sterile suspension is lyophilized.
- cryoprotective maltose, trehalose ... etc
- the addition of a cryoprotective is not essential, but promotes the resuspension of the lyophilisate.
- the average particle size remains unchanged after lyophilization.
- Example 4 Preparation of crosslinked human serum albumin nanoparticles.
- Example 2 The procedure is as in Example 1, but adding 0.06 g of a 25% (w / v) aqueous glutaraldehyde solution to phase 1. The average particle size remains unchanged after crosslinking.
- the procedure is as in Example 1, replacing SAH with SAB and replacing normal hydrochloric acid with the same amount of 0.01N sodium hydroxide.
- the average size of the nanoparticles is 150 nm with an average dispersion index of 0.5.
- SAB nanoparticles can be crosslinked, autoclaved and lyophilized like those of SAH.
- Example 6 Preparation of elastin nanoparticles.
- the procedure is as in Example 1, but replacing the SAH with elastin.
- the average size of the nanoparticles is 280 nm with an average dispersion index of 1.
- the elastin nanoparticles can be crosslinked, sterilized in an autoclave and lyophilized like those of SAH.
- Example 7 Adsorption of an active principle on protein nanoparticles.
- Example 8 Preparation of nanoparticles in the presence of an active principle.
- Example 1 The procedure is according to Example 1 (1g of SAH) or according to Example 5 (1g of SAB), but in the presence of 0.50g of sodium salicylate dissolved in phase 1.
- the average size of the nanoparticles is 200 nm with an average dispersion index of 0.5.
- the rate of fixation of sodium salicylate on the nanoparticles, measured after ultracentrifugation, is 60% of the amount used.
- Example 9 Variant of Example 8.
- Example 8 The procedure is as in Example 8, but the sodium salicylate is dissolved in phase 2.
- the nanoparticles obtained have the same characteristics as those of Example 8.
- Example 10 Preparation of doxorubicin protein nanoparticles.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Nanotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Colloid Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT89401856T ATE84710T1 (de) | 1988-06-30 | 1989-06-28 | Verfahren zur herstellung von kolloidalen dispergierbaren proteinsystemen, wie nanopartikeln. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR888808871A FR2634397B2 (fr) | 1986-12-31 | 1988-06-30 | Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules |
FR8808871 | 1988-06-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0349428A1 true EP0349428A1 (de) | 1990-01-03 |
EP0349428B1 EP0349428B1 (de) | 1993-01-20 |
Family
ID=9367939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP89401856A Expired - Lifetime EP0349428B1 (de) | 1988-06-30 | 1989-06-28 | Verfahren zur Herstellung von kolloidalen dispergierbaren Proteinsystemen, wie Nanopartikeln |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0349428B1 (de) |
JP (1) | JPH062224B2 (de) |
KR (1) | KR960014870B1 (de) |
AT (1) | ATE84710T1 (de) |
DE (1) | DE68904483T2 (de) |
ES (1) | ES2054052T3 (de) |
GR (1) | GR3007248T3 (de) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0449592A1 (de) * | 1990-03-27 | 1991-10-02 | Bioelastics Research, Ltd. | Bioelastomeres Arzneimittelabgabesystem |
WO1993010770A1 (de) * | 1991-12-05 | 1993-06-10 | Alfatec-Pharma Gmbh | Ein dihydropyridinderivat in nanosolform enthaltendes retard-arzneimittel und seine herstellung |
WO1993010762A1 (de) * | 1991-12-05 | 1993-06-10 | Alfatec-Pharma Gmbh | Ein ibuprofen enthaltendes akut-arzneimittel und seine verwendung |
WO1993010768A1 (de) * | 1991-12-05 | 1993-06-10 | Alfatec-Pharma Gmbh | Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung |
WO1999033558A1 (en) * | 1997-12-29 | 1999-07-08 | Universite De Geneve | Method for producing an aqueous colloidal dispersion of nanoparticles |
EP1683517A1 (de) | 1996-08-19 | 2006-07-26 | American Bioscience, Inc. | Methode zur Herstellung von Proteinpartkeln zur Freisetzung pharmakologischer Wirkstoffe |
EP2359859A1 (de) * | 2002-12-09 | 2011-08-24 | Abraxis BioScience, LLC | Zusammensetzungen, Albuminnanopartikel enthaltend und Methoden zur Freisetzung von Wirkstoffen |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
AU2002337692B2 (en) | 2001-09-26 | 2007-09-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
JP4290381B2 (ja) * | 2002-04-11 | 2009-07-01 | 学校法人 聖マリアンナ医科大学 | ピリドンカルボン酸化合物含有エマルション |
US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
DE102011002295B3 (de) | 2011-04-27 | 2012-08-30 | Mekra Lang Gmbh & Co. Kg | Längenverstellbare Außenspiegelanordnung |
DE202011000988U1 (de) | 2011-04-27 | 2011-07-01 | MEKRA Lang GmbH & Co. KG, 90765 | Längenverstellbare Außenspiegelanordnung |
DE102013022096B4 (de) * | 2013-12-20 | 2020-10-29 | Nanoval Gmbh & Co. Kg | Vorrichtung und Verfahren zum tiegelfreien Schmelzen eines Materials und zum Zerstäuben des geschmolzenen Materials zum Herstellen von Pulver |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3137631A (en) * | 1959-12-01 | 1964-06-16 | Faberge Inc | Encapsulation in natural products |
DE1542261A1 (de) * | 1965-03-05 | 1970-03-26 | Keuffel & Esser Co | Verfahren zur Herstellung von Fluessigkeiten oder feste Stoffe enthaltenden Kapseln |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2608988B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
FR2608942B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules |
-
1989
- 1989-06-28 EP EP89401856A patent/EP0349428B1/de not_active Expired - Lifetime
- 1989-06-28 DE DE8989401856T patent/DE68904483T2/de not_active Expired - Lifetime
- 1989-06-28 AT AT89401856T patent/ATE84710T1/de not_active IP Right Cessation
- 1989-06-28 ES ES89401856T patent/ES2054052T3/es not_active Expired - Lifetime
- 1989-06-29 KR KR1019890009022A patent/KR960014870B1/ko not_active IP Right Cessation
- 1989-06-30 JP JP1169743A patent/JPH062224B2/ja not_active Expired - Lifetime
-
1993
- 1993-03-05 GR GR930400469T patent/GR3007248T3/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3137631A (en) * | 1959-12-01 | 1964-06-16 | Faberge Inc | Encapsulation in natural products |
DE1542261A1 (de) * | 1965-03-05 | 1970-03-26 | Keuffel & Esser Co | Verfahren zur Herstellung von Fluessigkeiten oder feste Stoffe enthaltenden Kapseln |
Non-Patent Citations (1)
Title |
---|
PHARM. ACTA HELV., vol. 58, no. 7, 1983, pages 196-209, Zürich, CH; J. KREUTER: "Evaluation of nanoparticles as drug-delivery systems I: Preparation methods" * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6328996B1 (en) | 1990-03-27 | 2001-12-11 | Bioelastics Research Ltd. | Bioelastomeric drug delivery system |
EP0449592A1 (de) * | 1990-03-27 | 1991-10-02 | Bioelastics Research, Ltd. | Bioelastomeres Arzneimittelabgabesystem |
WO1993010770A1 (de) * | 1991-12-05 | 1993-06-10 | Alfatec-Pharma Gmbh | Ein dihydropyridinderivat in nanosolform enthaltendes retard-arzneimittel und seine herstellung |
WO1993010762A1 (de) * | 1991-12-05 | 1993-06-10 | Alfatec-Pharma Gmbh | Ein ibuprofen enthaltendes akut-arzneimittel und seine verwendung |
WO1993010768A1 (de) * | 1991-12-05 | 1993-06-10 | Alfatec-Pharma Gmbh | Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung |
EP1683517A1 (de) | 1996-08-19 | 2006-07-26 | American Bioscience, Inc. | Methode zur Herstellung von Proteinpartkeln zur Freisetzung pharmakologischer Wirkstoffe |
WO1999033558A1 (en) * | 1997-12-29 | 1999-07-08 | Universite De Geneve | Method for producing an aqueous colloidal dispersion of nanoparticles |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
EP2359859A1 (de) * | 2002-12-09 | 2011-08-24 | Abraxis BioScience, LLC | Zusammensetzungen, Albuminnanopartikel enthaltend und Methoden zur Freisetzung von Wirkstoffen |
US8138229B2 (en) | 2002-12-09 | 2012-03-20 | Abraxis Bioscience, Llc | Compositions and methods of delivery of pharmacological agents |
US8314156B2 (en) | 2002-12-09 | 2012-11-20 | Abraxis Bioscience, Llc | Compositions and methods of delivery of pharmacological agents |
US8846771B2 (en) | 2002-12-09 | 2014-09-30 | Abraxis Bioscience, Llc | Compositions and methods of delivery of pharmacological agents |
US9012518B2 (en) | 2002-12-09 | 2015-04-21 | Abraxis Bioscience, Llc | Compositions and methods of delivery of pharmacological agents |
US9012519B2 (en) | 2002-12-09 | 2015-04-21 | Abraxis Bioscience, Llc | Compositions and methods of delivery of pharmacological agents |
EP1585548B1 (de) * | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Zusammensetzungen, pharmakologisch wirksame agenzien enthaltend und wirkstofffreigabemethoden |
Also Published As
Publication number | Publication date |
---|---|
GR3007248T3 (de) | 1993-07-30 |
DE68904483D1 (de) | 1993-03-04 |
ATE84710T1 (de) | 1993-02-15 |
JPH062224B2 (ja) | 1994-01-12 |
DE68904483T2 (de) | 1993-05-19 |
KR910000128A (ko) | 1991-01-29 |
EP0349428B1 (de) | 1993-01-20 |
KR960014870B1 (ko) | 1996-10-21 |
ES2054052T3 (es) | 1994-08-01 |
JPH02149334A (ja) | 1990-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0349428B1 (de) | Verfahren zur Herstellung von kolloidalen dispergierbaren Proteinsystemen, wie Nanopartikeln | |
FR2634397A2 (fr) | Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules | |
EP0274961B1 (de) | Verfahren zur Herstellung eines kolloidalen, dispersiblen Systems von Nanokapseln | |
EP0275796B1 (de) | Herstellungsverfahren für kolloid-disperse Systeme aus einer Substanz in Form von Nanopartikeln | |
BE1000848A3 (fr) | Hydrosols de substances pharmacologiquement actives et compositions pharmaceutiques les contenant. | |
EP0934059B1 (de) | Methyliden-malonat nanopartikel, verfahren zu deren herstellung, und diese enthaltende pharmazeutische praeparate | |
EP0064967B1 (de) | Verfahren zur Erzeugung submikroskopischer Teilchen, auf diese Weise erhaltene Teilchen und pharmazeutische Produkte, welche die Teilchen enthalten | |
CA2447181C (fr) | Microcapsules a base de proteines vegetales | |
FR2721510A1 (fr) | Nanoparticules filtrables dans des conditions stériles. | |
EP1322411B1 (de) | Kolloidale suspension submikronischer teilchen der vektorisation aktiver prinzipien und deren herstellung | |
WO1985004106A1 (fr) | Ppocede de solubilisation de principes actifs et compositions pharmaceutiques ainsi obtenues | |
FR2571617A1 (fr) | Procede pour la microencapsulation par separation de phases de substances medicamenteuses hydrosolubles | |
EP0349429B1 (de) | Verfahren zur Herstellung dispergierbarer kolloidaler Systeme aus amphiphilen Lipiden in Form von Liposomen in Submikrongrösse | |
FR2598081A1 (fr) | Procede de preparation d'une solution pharmaceutique aqueuse d'un principe actif constitue par un acide organique | |
FR2934161A1 (fr) | Forme orale microparticulaire utile pour la liberation modifiee de nanoparticules. | |
WO1993025194A1 (fr) | Preparation et application de nouveaux systemes colloidaux nanovesiculaires dispersibles a base de cyclodextrine, sous forme de nanocapsules | |
FR2834215A1 (fr) | Composes amphiphiles a usage pharmaceutique ou cosmetique | |
FR2765496A1 (fr) | Microbilles appelees capsules a coeur polymerique capables de transporter des molecules, des principes actifs et/ou des cellules. | |
FR2793412A1 (fr) | Formulations galeniques d'argatroban pour administration sous-cutanee | |
FR2832312A1 (fr) | Procede de preparation de microparticules sans solvant toxique, microparticules obtenues selon ce procede, utilisations et compositions pharmaceutiques | |
WO2000067727A1 (fr) | Formulations galeniques d'agents antithrombiotques pour administration sous-cutanee |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19900702 |
|
17Q | First examination report despatched |
Effective date: 19910808 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 84710 Country of ref document: AT Date of ref document: 19930215 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 68904483 Country of ref document: DE Date of ref document: 19930304 |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 19930208 |
|
ITF | It: translation for a ep patent filed | ||
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3007248 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
EPTA | Lu: last paid annual fee | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2054052 Country of ref document: ES Kind code of ref document: T3 |
|
EAL | Se: european patent in force in sweden |
Ref document number: 89401856.3 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20080528 Year of fee payment: 20 Ref country code: CH Payment date: 20080527 Year of fee payment: 20 Ref country code: ES Payment date: 20080606 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20080526 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20080614 Year of fee payment: 20 Ref country code: BE Payment date: 20080528 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20080526 Year of fee payment: 20 Ref country code: NL Payment date: 20080626 Year of fee payment: 20 Ref country code: DE Payment date: 20080617 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20080630 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20080527 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20080527 Year of fee payment: 20 |
|
BE20 | Be: patent expired |
Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE *CNRS Effective date: 20090628 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20090627 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20090628 |
|
EUG | Se: european patent has lapsed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20090629 |
|
NLV7 | Nl: ceased due to reaching the maximum lifetime of a patent |
Effective date: 20090628 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20090629 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20090627 |